Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome

Clinical Nuclear Medicine - Tập 45 Số 4 - Trang 283-287 - 2020
Nils Schröter1,2, Ganna Blazhenets3, Lars Frings4,3, Christoph Barkhausen3, Wolfgang H. Jost5,6, Cornelius Weiller2, Michel Rijntjes2, Philipp T. Meyer3
1Berta-Ottenstein-Programme for Clinician Scientists
2Department of Neurology, Medical Center–University of Freiburg
3Department of Nuclear Medicine
4Center for Geriatrics and Gerontology Freiburg, Medical Center–University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg
5Germany
6Parkinson-Klinik Ortenau, Wolfach, Germany

Tóm tắt

Background and Objectives To evaluate tau PET using 11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) in the 4-repeat (4R)-tauopathies progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Methods Retrospective analysis of 11C-PBB3 PET in 2, 7, and 2 patients with CBS, PSP, and Alzheimer dementia (AD), respectively. Normalized 11C-PBB3 uptake in clusters with significant hypometabolism on 18F-FDG-PET and corresponding atlas-based volumes of interest was compared between diagnostic groups. Results In accordance with visually appreciable group differences, 11C-PBB3 uptake was significantly higher in dorsolateral frontal and motor cortex in CBS patients and frontal and temporal cortices in AD patients as compared with PSP patients. Patients with PSP showed mildly but significantly higher uptake in midbrain compared with AD patients. Conclusions In line with known neuropathological changes, the spatial pattern and magnitude of 11C-PBB3 tau binding differ between CBS, PSP, and AD, which may be of diagnostic utility. Thus, 11C-PBB3 offers a promising lead structure for development of ligands for tau imaging, including 4R-tauopathies.

Từ khóa


Tài liệu tham khảo

2010, Neuropathology of variants of progressive supranuclear palsy, Curr Opin Neurol, 23, 394, 10.1097/WCO.0b013e32833be924

2014, Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration, Neuropathology, 34, 555, 10.1111/neup.12143

2016, Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology, Brain, 139, 3237, 10.1093/brain/aww256

2011, Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome, Brain, 134, 3264, 10.1093/brain/awr234

2017, New diagnostics and therapeutics for progressive supranuclear palsy, Lancet Neurol, 16, 552, 10.1016/S1474-4422(17)30157-6

2002, How valid is the clinical diagnosis of Parkinson's disease in the community?, J Neurol Neurosurg Psychiatry, 73, 529, 10.1136/jnnp.73.5.529

2019, Tau PET imaging in neurodegenerative tauopathies—still a challenge, Mol Psychiatr, 24, 1112, 10.1038/s41380-018-0342-8

2017, 18F-flortaucipir tau PET distinguishes established progressive supranuclear palsy from controls and Parkinson's disease: a multicenter study, Ann Neurol, 82, 622, 10.1002/ana.25060

2017, 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome, Neurology, 89, 1170, 10.1212/WNL.0000000000004364

2015, Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue, Ann Neurol, 78, 787, 10.1002/ana.24517

2013, Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls, Neuron, 79, 1094, 10.1016/j.neuron.2013.07.037

2017, PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins, Mov Disord, 32, 1016, 10.1002/mds.27029

2019, In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy, Mov Disord, 34, 744, 10.1002/mds.27643

2018, PBB3 binding in a patient with corticobasal syndrome, Mov Disord, 33, 1359, 10.1002/mds.27405

2017, Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology, Mov Disord, 32, 884, 10.1002/mds.27013

2014, Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology, J Nucl Med, 55, 1532, 10.2967/jnumed.114.139550

2015, PET quantification of tau pathology in human brain with 11C-PBB3, J Nucl Med, 56, 1359, 10.2967/jnumed.115.160127

2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005

2013, Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, 496, 10.1212/WNL.0b013e31827f0fd1

2017, Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria, Mov Disord, 32

2002, Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, Neuroimage, 15, 273, 10.1006/nimg.2001.0978

2008, Construction of a 3D probabilistic atlas of human cortical structures, Neuroimage, 39, 1064, 10.1016/j.neuroimage.2007.09.031

2019, FDG-PET patterns associated with underlying pathology in corticobasal syndrome, Neurology, 92, e1121, 10.1212/WNL.0000000000007038

1999, Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration, J Neurol, 246, II6

2017, Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy, Mov Disord, 32, 134, 10.1002/mds.26844

2017, Imaging tau pathology in parkinsonisms, NPJ Parkinsons, 3, 22, 10.1038/s41531-017-0023-3

2018, The development and validation of tau PET tracers: current status and future directions, Clin Transl Imaging, 6, 305, 10.1007/s40336-018-0290-y

2017, In vivo retention of 18F-AV-1451 in corticobasal syndrome, Neurology, 89, 845, 10.1212/WNL.0000000000004264

2017, 18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment, J Nucl Med, 58, 1888, 10.2967/jnumed.116.186403

Thông tin
Thông tin xuất bản

Clinical Nuclear Medicine

Tập 45 Số 4

283-287

Thông tin tác giả